OU Daily at the University of Oklahoma recently published a story on research being conducted by Dr. Wei R. Chen on IP-001’s potential application as an immune-system booster that could be used in conjunction with a COVID-19 vaccine. The story is available here.
Category: Latest News
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 04:13 ET | Source: Immunophotonics, Inc. BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board...
Immunophotonics Receives Swissmedic Approval to Commence Phase 1B/2A Clinical Trial in Switzerland
Immunophotonics has received Swissmedic approval to commence a new clinical trial entitled “Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.” This is a multicenter phase 1B/2A trial with expansion cohorts in melanoma and soft tissue sarcoma patients. The therapeutic approach taken by this trial (SAKK 66/17) is different from those...
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and IRVINE, Calif., June 14, 2019 (GLOBE NEWSWIRE) — Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial...